Pembrolizumab demonstrated promising efficacy and safety in anaplastic thyroid cancer based on pooled survival and tumor ...

Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations, a ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in ...

Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung cancer.